KR880007073A - 의 약 품 - Google Patents

의 약 품 Download PDF

Info

Publication number
KR880007073A
KR880007073A KR870014390A KR870014390A KR880007073A KR 880007073 A KR880007073 A KR 880007073A KR 870014390 A KR870014390 A KR 870014390A KR 870014390 A KR870014390 A KR 870014390A KR 880007073 A KR880007073 A KR 880007073A
Authority
KR
South Korea
Prior art keywords
methyl
active ingredient
carbazole
tetrahydro
per unit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR870014390A
Other languages
English (en)
Korean (ko)
Inventor
브라이언 타이어스 마이클
Original Assignee
배리 안토니 뉴샘
글락소 그룹 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 배리 안토니 뉴샘, 글락소 그룹 리미티드 filed Critical 배리 안토니 뉴샘
Publication of KR880007073A publication Critical patent/KR880007073A/ko
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Emergency Protection Circuit Devices (AREA)
  • Connection Of Batteries Or Terminals (AREA)
  • Saccharide Compounds (AREA)
  • Electrotherapy Devices (AREA)
KR870014390A 1986-12-17 1987-12-17 의 약 품 Ceased KR880007073A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB868630071A GB8630071D0 (en) 1986-12-17 1986-12-17 Medicaments
GB8630071 1986-12-17

Publications (1)

Publication Number Publication Date
KR880007073A true KR880007073A (ko) 1988-08-26

Family

ID=10609112

Family Applications (1)

Application Number Title Priority Date Filing Date
KR870014390A Ceased KR880007073A (ko) 1986-12-17 1987-12-17 의 약 품

Country Status (18)

Country Link
US (1) US4835173A (enExample)
EP (1) EP0276559B1 (enExample)
JP (1) JP2732844B2 (enExample)
KR (1) KR880007073A (enExample)
AT (1) ATE79031T1 (enExample)
AU (1) AU608794B2 (enExample)
CY (1) CY1693A (enExample)
DE (1) DE3780940T2 (enExample)
DK (1) DK662787A (enExample)
ES (1) ES2051754T3 (enExample)
GB (1) GB8630071D0 (enExample)
GR (1) GR3005682T3 (enExample)
HK (1) HK36593A (enExample)
IE (1) IE60135B1 (enExample)
IL (1) IL84844A0 (enExample)
NZ (1) NZ222949A (enExample)
PH (1) PH25503A (enExample)
ZA (1) ZA879458B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3788057T2 (de) * 1986-12-17 1994-03-03 Glaxo Group Ltd Verwendung von heterocyclischen Verbindungen zur Behandlung von Depressionen.
US5246941A (en) 1986-12-17 1993-09-21 Glaxo Group Limited Method for the treatment of depression
US5221687A (en) * 1988-09-01 1993-06-22 Glaxo Group Limited Medicaments
GB8820653D0 (en) * 1988-09-01 1988-10-05 Glaxo Group Ltd Medicaments
US5180728A (en) * 1989-09-25 1993-01-19 Fujisawa Pharmaceutical Company, Ltd. Pyrimidoindole derivatives and processes for preparation thereof
US5225407A (en) * 1990-02-22 1993-07-06 Glaxo Group Limited 5-HT3 receptor antagonists for the treatment of autism
CA2112487C (en) * 1991-06-26 2003-04-15 James W. Young Method and compositions for treating emesis, nausea and other disorders using optically pure r(+) ondansetron
WO2000051582A2 (en) 1999-03-01 2000-09-08 Sepracor Inc. Methods for treating apnea and apnea disorders using optically pure r(+)ondansetron
US20020107275A1 (en) * 2000-10-30 2002-08-08 Ramy Lidor-Hadas Novel crystal and solvate forms of ondansetron hydrochloride and processes for their preparation
EP1207160A1 (en) * 2000-11-20 2002-05-22 Hanmi Pharm. Co., Ltd. Process for the preparation of 1,2,3,9-tetrahydro-9-methyl-3-((2-methyl-1H-imidazol-1-yl)-methyl)-4H-carbazol-4-one
US20020115707A1 (en) * 2001-01-11 2002-08-22 Rami Lidor-Hadas Process for preparing pure ondansetron hydrochloride dihydrate
KR20070054749A (ko) * 2001-01-11 2007-05-29 테바 파마슈티컬 인더스트리즈 리미티드 순수한 온단세트론 하이드로클로라이드 이수화물의 개선된제조 방법
CN1665823A (zh) 2002-04-29 2005-09-07 特瓦药厂有限公司 制备1,2,3,9-四氢-9-甲基-3-[(2-甲基-1h-咪唑-1-基)甲基]-4h-咔唑-4-酮的方法
US20050131045A1 (en) * 2002-04-30 2005-06-16 Judith Aronhime Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical, compositions containing the novel forms and methods for treating nausea using them
US20040019093A1 (en) * 2002-04-30 2004-01-29 Judith Aronhime Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical compositions containing the novel forms and methods for treating nausea using them
HU225885B1 (en) * 2002-10-17 2007-11-28 Richter Gedeon Nyrt Process for producing ondansetron hydrochlorid dihydrate of high purity
US20110034442A1 (en) * 2007-08-08 2011-02-10 Jaun Jose Legarda Ibanez Use and Methods of Use for an Antagonist of the Serotin3 Receptor (5-HT3) and a Selective Modulator of Chloride Channels for the Treatment of Addiction to or Dependence on Medicines/Drugs or Nervous System Disorders
WO2019242982A2 (en) * 2018-06-21 2019-12-26 Societe Des Produits Nestle S.A. Compositions and methods using a nicotinamide adenine dinucleotide (nad+) precursor and at least one ketone or ketone precursor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN158970B (enExample) * 1981-06-09 1987-02-28 Ici Plc
GB8401888D0 (en) * 1984-01-25 1984-02-29 Glaxo Group Ltd Heterocyclic compounds
DE19375046I2 (de) * 1984-01-25 2002-10-10 Glaxo Group Ltd 1,2,3,9-Tetrahydro-3-Ä(1H-imidazol-1-yl)methylÜ-4H-carbazol-4-one Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Zubereitungen
EP0201165B1 (en) * 1985-03-14 1994-07-20 Beecham Group Plc Medicaments for the treatment of emesis
GB8516083D0 (en) * 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
GB8518743D0 (en) * 1985-07-24 1985-08-29 Glaxo Group Ltd Heterocyclic compounds
NL8701682A (nl) * 1986-07-30 1988-02-16 Sandoz Ag Werkwijze voor het therapeutisch toepassen van serotonine antagonisten, aktieve verbindingen en farmaceutische preparaten die deze verbindingen bevatten.

Also Published As

Publication number Publication date
IE60135B1 (en) 1994-06-01
EP0276559A2 (en) 1988-08-03
DK662787D0 (da) 1987-12-16
JP2732844B2 (ja) 1998-03-30
DE3780940T2 (de) 1992-12-24
GB8630071D0 (en) 1987-01-28
GR3005682T3 (enExample) 1993-06-07
ATE79031T1 (de) 1992-08-15
JPS63165314A (ja) 1988-07-08
ES2051754T3 (es) 1994-07-01
PH25503A (en) 1991-07-24
AU8261787A (en) 1988-06-23
NZ222949A (en) 1997-06-24
EP0276559A3 (en) 1989-10-18
US4835173A (en) 1989-05-30
AU608794B2 (en) 1991-04-18
EP0276559B1 (en) 1992-08-05
DE3780940D1 (de) 1992-09-10
IL84844A0 (en) 1988-06-30
DK662787A (da) 1988-06-18
HK36593A (en) 1993-04-23
IE873415L (en) 1988-06-17
CY1693A (en) 1994-01-14
ZA879458B (en) 1988-11-30

Similar Documents

Publication Publication Date Title
KR880007073A (ko) 의 약 품
KR880007074A (ko) 의약품
CA2105180A1 (en) Compositions containing sumatriptan
KR950031069A (ko) 골손실의 억제 및 혈청 콜레스테롤의 강하 방법
PT99340B (pt) Processo para a preparacao de composicoes farmaceuticas anticoncepcionais contendo um estrogenio em mistura com 16-metileno-17 alfa-acetoxi-19-nor-4-pregneno-3,20-diona para administracao por via transdermica e dispositivo para a realizacao da administracao
GEP20043324B (en) Purine Derivatives
EP0724885A4 (en) COMPOSITION ADMINISTERED BY NASAL AND PREPARATION CONTAINING THE SAME
KR880005930A (ko) 탐닉 치료용 의약품
HUP0105173A2 (hu) Adagolási módszer és készítmény sürgősségi fogamzásgátlásra
KR880002515A (ko) 흡수 및 작용이 빠른 설린다크 또는 나트륨 설린다크와 염기의 혼합물
HK1042303A1 (zh) 新的化合物
KR970025615A (ko) 암 전이 억제제
KR880007079A (ko) 레트로비루스에 감염된 환자치료에 있어서의 3'-디옥시티미딘-2'-엔(3'-디옥시-2',3'-디디하이드로티미딘)의 사용법
KR880007060A (ko) 제약 조성물
EP0005015B1 (en) Use of a xanthine derivate in the manufacture of a medicament
HUP9900507A2 (hu) Levobupivacaine alkalmazása terhesség esetén használható érzéstelenítő hatású gyógyszerkészítmények előállítására
OA07029A (fr) Le chlorure de gallium, nouveau médicament anti-cancéreux.
TR200103144T2 (tr) Yeni bileşikler
KR890014109A (ko) 의약제
KR910004190A (ko) 온단세트론의 신규 의학 용도
CA2450915A1 (en) Use of levosimendan and beta-adrenergic receptor antagonist for the treatment of heart failure
RU95110494A (ru) Средство с регулируемым высвобождением пентоксифиллина для лечения сосудистых заболеваний
KR890007728A (ko) 진통제 제조방법
KR830008678A (ko) 진통 조성물
IT8247658A1 (it) Medicamenti a base di derivati condensati dell'imidazolo per il trattamento di disturbi urinari

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19871217

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19921216

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19871217

Comment text: Patent Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19951012

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 19960402

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 19951012

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I